- Home
- ENGN vs TERN Comparison
ENGN vs TERN Comparison
Compare ENGN & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- TERN
- Stock Information
- Founded
- ENGN 1999
- TERN 2017
- Country
- ENGN Canada
- TERN United States
- Employees
- ENGN N/A
- TERN N/A
- Industry
- ENGN
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- ENGN
- TERN Health Care
- Exchange
- ENGN Nasdaq
- TERN Nasdaq
- Market Cap
- ENGN 297.7M
- TERN 355.9M
- IPO Year
- ENGN N/A
- TERN 2021
- Fundamental
- Price
- ENGN $5.25
- TERN $3.49
- Analyst Decision
- ENGN Buy
- TERN Buy
- Analyst Count
- ENGN 9
- TERN 5
- Target Price
- ENGN $25.89
- TERN $18.30
- AVG Volume (30 Days)
- ENGN 56.3K
- TERN 1.1M
- Earning Date
- ENGN 03-18-2025
- TERN 03-17-2025
- Dividend Yield
- ENGN N/A
- TERN N/A
- EPS Growth
- ENGN N/A
- TERN N/A
- EPS
- ENGN N/A
- TERN N/A
- Revenue
- ENGN N/A
- TERN N/A
- Revenue This Year
- ENGN N/A
- TERN N/A
- Revenue Next Year
- ENGN N/A
- TERN N/A
- P/E Ratio
- ENGN N/A
- TERN N/A
- Revenue Growth
- ENGN N/A
- TERN N/A
- 52 Week Low
- ENGN $4.42
- TERN $3.27
- 52 Week High
- ENGN $18.40
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- ENGN 34.69
- TERN 31.45
- Support Level
- ENGN $5.14
- TERN $3.27
- Resistance Level
- ENGN $5.98
- TERN $3.68
- Average True Range (ATR)
- ENGN 0.62
- TERN 0.23
- MACD
- ENGN -0.04
- TERN 0.00
- Stochastic Oscillator
- ENGN 5.91
- TERN 22.03
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.